Publication GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer (ACS Publications, 2021) Learn More
White Paper Thinking with the End in Mind: How CAR-T Early Discovery Decisions Impact Your IND Learn More
